Matching articles for "Novolog"
Issue 1743 · December 8, 2025
Insulins for Type 2 Diabetes

The goal of pharmacologic treatment for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration while minimizing hypoglycemia; an A1C goal of <7% is recommended for…

Med Lett Drugs Ther. 2025 Dec 8; 67(1743):196-9 doi:10.58347/tml.2025.1743c
The goal of pharmacologic treatment for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration while minimizing hypoglycemia; an A1C goal of <7% is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk for serious hypoglycemia-associated adverse events.
Issue 1743 · December 8, 2025 Free
Comparison Chart: Some Available Insulins for Type 2 Diabetes (online only)

View the Comparison Chart: Some Available Insulins for Type 2 Diabetes

Med Lett Drugs Ther. 2025 Dec 8; 67(1743):e201-4 doi:10.58347/tml.2025.1743d
View the Comparison Chart: Some Available Insulins for Type 2 Diabetes
Issue 1741 · November 10, 2025 Free
In Brief: Kirsty — An Insulin Aspart Interchangeable with NovoLog (online only)

The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US…

Med Lett Drugs Ther. 2025 Nov 10; 67(1741):e185-6 doi:10.58347/tml.2025.1741g
The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US that has received interchangeability status with NovoLog ; Merilog , another insulin aspart biosimilar, was approved earlier but has not received interchangeability status with NovoLog .
Issue 1731 · June 23, 2025 Free
In Brief: Merilog — A NovoLog Biosimilar

The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar…

Med Lett Drugs Ther. 2025 Jun 23; 67(1731):104 doi:10.58347/tml.2025.1731c
The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar product to become available in the US.
Issue 1609 · October 19, 2020
Lyumjev - A New Insulin Lispro for Diabetes

The FDA has approved insulin lispro-aabc ( Lyumjev – Lilly), a faster-acting formulation of insulin lispro (Humalog) , for treatment of type 1 and type 2 diabetes in adults. Fiasp , a faster-acting…

Med Lett Drugs Ther. 2020 Oct 19; 62(1609):162-3
The FDA has approved insulin lispro-aabc ( Lyumjev – Lilly), a faster-acting formulation of insulin lispro (Humalog) , for treatment of type 1 and type 2 diabetes in adults. Fiasp , a faster-acting formulation of insulin aspart (Novolog) , was approved in 2017.
Issue 1571 · May 6, 2019
Insulins for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin…

Med Lett Drugs Ther. 2019 May 6; 61(1571):65-8
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin is the preferred first-line treatment, but most patients with type 2 diabetes eventually require multidrug therapy and/or insulin to achieve glycemic control.
Issue 1571 · May 6, 2019
Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)

View the Expanded Table: Some Available Insulins

Med Lett Drugs Ther. 2019 May 6; 61(1571):e73-7
View the Expanded Table: Some Available Insulins
Issue 1537 · January 1, 2018
Fiasp - Another Insulin Aspart Formulation for Diabetes

The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional…

Med Lett Drugs Ther. 2018 Jan 1; 60(1537):6-7
The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart (Novolog) .
Issue 1512 · January 16, 2017
Drugs for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to…

Med Lett Drugs Ther. 2017 Jan 16; 59(1512):9-18
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to this target has been shown to prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular outcomes is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease, a history of severe hypoglycemia, diabetes-related complications or comorbidities, or a long duration of disease.
Issue 1463 · March 2, 2015
An Inhaled Insulin (Afrezza)

The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin ( Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1…

Med Lett Drugs Ther. 2015 Mar 2; 57(1463):34-5
The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin ( Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1 diabetes, the drug must be used in combination with long-acting insulin. Another inhaled, rapid-acting insulin (Exubera) was approved in 2006 for the same indication, but was withdrawn from the market the following year.
Issue 139 · March 1, 2014
Drugs for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal A1C concentration without inducing hypoglycemia; the target is generally an A1C of <7.0%. Treating to this target has been…

Treat Guidel Med Lett. 2014 Mar; 12(139):17-24
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal A1C concentration without inducing hypoglycemia; the target is generally an A1C of <7.0%. Treating to this target has been shown to prevent the microvascular complications of retinopathy and nephropathy, but whether it prevents macrovascular outcomes remains unclear. Three large trials found that intensive glucose control did not reduce the incidence of macrovascular events. One of these trials (ACCORD) in >10,000 patients with type 2 diabetes, with or at high-risk for cardiovascular disease, found that treating patients intensively with antihyperglycemic drugs to an A1C target of 6.0% for a mean of 3.7 years did not significantly reduce the incidence of major cardiovascular events (the primary endpoint) and was associated with increased all-cause mortality compared to patients treated to an A1C target of 7.0-7.9%. An A1C target of 7-8% may be prudent in older patients and in those with underlying cardiovascular disease, severe hypoglycemia, or multiple diabetes-related complications or co-morbidities.
Issue 108 · August 1, 2011
Drugs for Type 2 Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities that includes insulin resistance, diminished insulin secretion and excess hepatic glucose production.…

Treat Guidel Med Lett. 2011 Aug; 9(108):47-54
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities that includes insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy.
Issue 1327 · December 14, 2009
Rapid-Acting Insulin Analogues

Three rapid-acting insulin analogs are currently available: insulin lispro, insulin aspart and insulin glulisine. 1-3 All three are approved for use in both type 1 and type 2 diabetes, either by subcutaneous…

Med Lett Drugs Ther. 2009 Dec 14; 51(1327):98
Three rapid-acting insulin analogs are currently available: insulin lispro, insulin aspart and insulin glulisine. 1-3 All three are approved for use in both type 1 and type 2 diabetes, either by subcutaneous injection, insulin pump or intravenous administration. All three cost more than regular insulin.
Issue 71 · July 1, 2008
Drugs for Type 2 Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet,…

Treat Guidel Med Lett. 2008 Jul; 6(71):47-6
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy.
Issue 1238 · July 3, 2006
Insulin Detemir (Levemir), a New Long-Acting Insulin

Insulin detemir ( Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the…

Med Lett Drugs Ther. 2006 Jul 3; 48(1238):54-5
Insulin detemir ( Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in position B30 and the addition of a 14-carbon fatty acid chain at position B29. Insulin glargine (Lantus) , the first long-acting insulin analog, has been available since 2001 and is usually given once daily.1 NPH insulin is an intermediate-acting basal insulin given twice daily. Basal insulins are usually combined with prandial doses of a rapid-acting insulin.
Issue 1233 · April 24, 2006
Insulin Glulisine (Apidra) -- A New Rapid-Acting Insulin

Insulin glulisine ( Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog) . All three have a more rapid…

Med Lett Drugs Ther. 2006 Apr 24; 48(1233):33-4
Insulin glulisine ( Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog) . All three have a more rapid onset and shorter duration of action than regular human insulin. Rapid-acting insulin analogs are generally taken immediately before meals and are usually combined with a long-acting basal insulin.
Issue 36 · August 1, 2005
Drugs for Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In…

Treat Guidel Med Lett. 2005 Aug; 3(36):57-62
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In many patients, diet and regular exercise can improve glucose control. Most drugs currently available for management of type 2 diabetes increase insulin supply (sulfonylureas, other secretagogues and insulin itself), decrease insulin resistance (thiazolidinediones) or improve the effectiveness of insulin (biguanides). Alpha-glucosidase inhibitors reduce the rate of glucose absorption. Newer agents such as pramlintide (Symlin) and exenatide (Byetta) have multiple effects to increase satiety and reduce postprandial hyperglycemia.
Issue 1 · September 1, 2002
Drugs for Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most…

Treat Guidel Med Lett. 2002 Sep; 0(1):1-6
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most drugs currently available for management of type 2 diabetes fall into 2 categories: those that increase insulin supply (sulfonylureas, other secretagogues and insulin itself) and those that decrease insulin resistance or improve its effectiveness (biguanides, thiazolidinediones). Alpha-glucosidase inhibitors reduce the rate of glucose absorption.
Issue 1115 · October 15, 2001
Insulin Aspart, A New Rapid-acting Insulin

Insulin aspart ( Novolog - Novo Nordisk) is the second rapid-acting insulin analog to be approved by the FDA. The first was insulin lispro (Humalog) . Insulin aspart differs from human insulin by substitution…

Med Lett Drugs Ther. 2001 Oct 15; 43(1115):89-90
Insulin aspart ( Novolog - Novo Nordisk) is the second rapid-acting insulin analog to be approved by the FDA. The first was insulin lispro (Humalog) . Insulin aspart differs from human insulin by substitution of aspartic acid for proline in position 28 on the beta-chain.